Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

The letter specifies violations at its Halol facility, with regards to manufacturing of goods.

FPJ Web DeskUpdated: Friday, December 16, 2022, 07:35 PM IST
article-image
Representational image |

Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.

The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.

RECENT STORIES

After RBI Action, Kotak Bank Shares Stumble Nearly 10%; Markets Start In Red

After RBI Action, Kotak Bank Shares Stumble Nearly 10%; Markets Start In Red

Mitesh Mangaonkar: Leading Innovator In Data Engineering And Cloud Computing

Mitesh Mangaonkar: Leading Innovator In Data Engineering And Cloud Computing

‘Tax Payers Are Meaningless Minorities': Only 0.5% Of Voters Pay Income Tax, Says Ashneer Grover

‘Tax Payers Are Meaningless Minorities': Only 0.5% Of Voters Pay Income Tax, Says Ashneer Grover

'Cease And Desist': RBI Bars Kotak Mahindra Bank From Onboarding New Customers Via Online, Issuing...

'Cease And Desist': RBI Bars Kotak Mahindra Bank From Onboarding New Customers Via Online, Issuing...

Ultraviolette Launches F77 Mach 2 in India: Promises 323km Range at Rs 2.99 Lakh

Ultraviolette Launches F77 Mach 2 in India: Promises 323km Range at Rs 2.99 Lakh